KR20240012538A - Map4k1 억제제로 사용하기 위한 피리미딘 화합물 - Google Patents
Map4k1 억제제로 사용하기 위한 피리미딘 화합물 Download PDFInfo
- Publication number
- KR20240012538A KR20240012538A KR1020237044454A KR20237044454A KR20240012538A KR 20240012538 A KR20240012538 A KR 20240012538A KR 1020237044454 A KR1020237044454 A KR 1020237044454A KR 20237044454 A KR20237044454 A KR 20237044454A KR 20240012538 A KR20240012538 A KR 20240012538A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- chloro
- methoxy
- tetrahydroisoquinolin
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121030204 | 2021-07-06 | ||
| IN202121030204 | 2021-07-06 | ||
| PCT/IB2022/056248 WO2023281417A1 (en) | 2021-07-06 | 2022-07-06 | Pyrimidine compounds for use as map4k1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240012538A true KR20240012538A (ko) | 2024-01-29 |
Family
ID=82703212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237044454A Ceased KR20240012538A (ko) | 2021-07-06 | 2022-07-06 | Map4k1 억제제로 사용하기 위한 피리미딘 화합물 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12577267B2 (https=) |
| EP (1) | EP4367123A1 (https=) |
| JP (1) | JP2024527565A (https=) |
| KR (1) | KR20240012538A (https=) |
| CN (1) | CN117730083A (https=) |
| AU (1) | AU2022305807B2 (https=) |
| CA (1) | CA3223874A1 (https=) |
| CL (1) | CL2023003791A1 (https=) |
| CO (1) | CO2024000572A2 (https=) |
| EC (1) | ECSP24007193A (https=) |
| IL (1) | IL309342A (https=) |
| MX (1) | MX2023015246A (https=) |
| PE (1) | PE20240585A1 (https=) |
| WO (1) | WO2023281417A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024231875A1 (en) | 2023-05-09 | 2024-11-14 | Glenmark Specialty S.A. | Hpk1 inhibitor for use in the treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2792979T3 (es) * | 2013-08-22 | 2020-11-12 | Jubilant Biosys Ltd | Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos |
| WO2018102366A1 (en) * | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| AU2020406824A1 (en) * | 2019-12-16 | 2022-08-11 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
-
2022
- 2022-07-06 CA CA3223874A patent/CA3223874A1/en active Pending
- 2022-07-06 EP EP22747756.9A patent/EP4367123A1/en not_active Withdrawn
- 2022-07-06 US US17/912,729 patent/US12577267B2/en active Active
- 2022-07-06 AU AU2022305807A patent/AU2022305807B2/en not_active Expired - Fee Related
- 2022-07-06 PE PE2023003341A patent/PE20240585A1/es unknown
- 2022-07-06 WO PCT/IB2022/056248 patent/WO2023281417A1/en not_active Ceased
- 2022-07-06 CN CN202280048104.2A patent/CN117730083A/zh active Pending
- 2022-07-06 KR KR1020237044454A patent/KR20240012538A/ko not_active Ceased
- 2022-07-06 IL IL309342A patent/IL309342A/en unknown
- 2022-07-06 MX MX2023015246A patent/MX2023015246A/es unknown
- 2022-07-06 JP JP2024500151A patent/JP2024527565A/ja active Pending
-
2023
- 2023-12-19 CL CL2023003791A patent/CL2023003791A1/es unknown
-
2024
- 2024-01-24 CO CONC2024/0000572A patent/CO2024000572A2/es unknown
- 2024-01-26 EC ECSENADI20247193A patent/ECSP24007193A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022305807A1 (en) | 2024-01-04 |
| AU2022305807B2 (en) | 2024-09-05 |
| JP2024527565A (ja) | 2024-07-25 |
| US20230227483A1 (en) | 2023-07-20 |
| MX2023015246A (es) | 2024-01-19 |
| CN117730083A (zh) | 2024-03-19 |
| US12577267B2 (en) | 2026-03-17 |
| WO2023281417A1 (en) | 2023-01-12 |
| CA3223874A1 (en) | 2023-01-12 |
| PE20240585A1 (es) | 2024-03-21 |
| CL2023003791A1 (es) | 2024-07-12 |
| CO2024000572A2 (es) | 2024-02-05 |
| IL309342A (en) | 2024-02-01 |
| ECSP24007193A (es) | 2024-03-01 |
| EP4367123A1 (en) | 2024-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7451765B2 (ja) | Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途 | |
| US11242334B2 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| JP6461097B2 (ja) | Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 | |
| CN107072985B (zh) | 治疗性抑制化合物 | |
| CN115703775A (zh) | 一种kras突变体g12c抑制剂及其制备方法和应用 | |
| JP6457623B2 (ja) | ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用 | |
| CN112601752A (zh) | Map4k1的新颖抑制剂 | |
| JP7101311B2 (ja) | Ｍａｐ４ｋ１阻害剤として使用するためのインドリノン化合物 | |
| CN113508116B (zh) | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 | |
| WO2013170774A1 (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
| WO2018045957A1 (zh) | 一种cdk4/6抑制剂及其制备方法和应用 | |
| TW201619150A (zh) | 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物 | |
| JP2018505207A (ja) | 置換モノおよびポリアザナフタレン誘導体およびその使用 | |
| TW201506028A (zh) | １，２-雙取代雜環化合物 | |
| TWI601724B (zh) | 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用 | |
| KR20250033148A (ko) | Parp1 억제제로서의 화합물 | |
| EP3302484A1 (en) | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors | |
| CN116396228B (zh) | 尿嘧啶类parp7抑制剂 | |
| CN119451964A (zh) | Fgfr2和fgfr3抑制剂及其用途 | |
| WO2021197250A1 (zh) | 作为转染期间重排激酶抑制剂的新的化合物 | |
| JP2022544700A (ja) | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 | |
| KR20240012538A (ko) | Map4k1 억제제로 사용하기 위한 피리미딘 화합물 | |
| EA048523B1 (ru) | Пиримидиновые соединения для применения в качестве ингибиторов map4k1 | |
| OA21470A (en) | Pyrimidine compounds for use as MAP4K1 inhibitors. | |
| WO2025234404A1 (ja) | ピリミジン含有縮合環化合物及びその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |